muraglitazar muraglitazar muraglitazar (proposed tradename pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to pparα and pparγ. muraglitazarclinical dataother names2-phenyl]methyl]amino]acetic acidatc codenonelegal statuslegal status development terminated identifiers iupac name n--n-glycine cas number331741-94-7 ypubchem cid206044chemspider178524 nuniiw1mkm70wqikeggd05091 ychemblchembl557580 ncomptox dashboard (epa)dtxsid9057719 chemical and physical dataformulac29h28n2o7molar mass516.550 g·mol−13d model (jsmol)interactive image smiles cc1=c(n=c(o1)c2=cc=cc=c2)ccoc3=cc=c(c=c3)cn(cc(=o)o)c(=o)oc4=cc=c(c=c4)oc inchi inchi=1s/c29h28n2o7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15h,16-19h2,1-2h3,(h,32,33) nkey:irlwjillxjgjtd-uhfffaoysa-n n ny (what is this?) (verify) the drug had completed phase iii clinical trials, however in may, 2006 bristol-myers squibb announced that it had discontinued further development. data on muraglitazar is relatively sparse due to the recent introduction of this agent. one double-blind randomized clinical trial comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of hdl-c increase, decrease in total cholesterol, apolipoprotein b, triglycerides and a greater reduction in hba1c (p <0.0001 for all comparisons). however, the muraglitazar group had a higher all-cause mortality, greater incidence of edema and heart failure and more weight gain compared to the pioglitazone group. a meta-analysis of the phase ii and iii clinical trials of muraglitazar revealed that it was associated with a greater incidence of myocardial infarction, stroke, transient ischemic attacks and congestive heart failure (chf) when compared to placebo or pioglitazone. by calling attention to adverse events made public through the fda advisory committee process, dr nissen came upon a mechanism to steer fda from the outside. this mechanism came to fruition with rosiglitazone (avandia)and led to fda requiring demonstration of cardiac safety for new drugs to treat type 2 diabetes. this process is described by dr robert misbin in insulin-history from an fda insider, published june 1, 2020 on amazon.